購物車
幫助
021-54845833/15800441009
|
Background: |
The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The family member CHRNA7, which is located on chromosome 15 in a region associated with several neuropsychiatric disorders, is partially duplicated and forms a hybrid with a novel gene from the family with sequence similarity 7 (FAM7A). Alternative splicing has been observed, and two variants exist, for this hybrid gene. The N-terminally truncated products predicted by the largest open reading frames for each variant would lack the majority of the neurotransmitter-gated ion-channel ligand binding domain but retain the transmembrane region that forms the ion channel. Although current evidence supports transcription of this hybrid gene, translation of the nicotinic acetylcholine receptor-like protein-encoding open reading frames has not been confirmed. |
|
Applications: |
ELISA, WB, IHC |
|
Name of antibody: |
CHRFAM7A |
|
Immunogen: |
Synthetic peptide of human CHRFAM7A |
|
Full name: |
CHRNA7 (cholinergic receptor, nicotinic, alpha 7, exons 5-10) and FAM7A (family with sequence similarity 7A, exons A-E) fusion |
|
Synonyms： |
D-10, CHRNA7, CHRNA7-DR1 |
|
SwissProt: |
P36544 |
|
ELISA Recommended dilution: |
2000-5000 |
|
IHC positive control: |
Human liver cancer and Human cervical cancer |
|
IHC Recommend dilution: |
25-100 |
|
WB Predicted band size: |
46 kDa |
|
WB Positive control: |
Mouse heart tissue |
|
WB Recommended dilution: |
500-2000 |
